Andrew Paulson is an Oncology physician affiliated with The US Oncology Network. OpenAlex indexes 184 publications with 6,565 citations (h-index 19).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3410 Worth St
Dallas, TX 752462003
Telephone
214-370-1000Provider last certified this registry record 1 Jun 2021.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Exelixis Inc.Program year20253 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
- Amgen Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57%PD-1 inhibitor25.7%Pembrolizumab72%Nivolumab28%Part B, office-administered≥29 patientsPlatinum-based Drug12.1%Oxaliplatin98%Carboplatin3%Part B, office-administered≥19 patients+ 5 more classes in this area
Metabolism & gastrointestinal
26.1%Other antiemetics22.4%Fosaprepitant100%Part B, office-administered≥53 patientsSerotonin-3 Receptor Antagonist3.4%Palonosetron hcl65%Granisetron hydrochloride34%Ondansetron Hcl2%Part D + Part B<11 patients+ 4 more classes in this area
Hormonal (systemic)
12.1%Somatostatin Analog12.1%Lanreotide100%Octreotide Acetate0%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Vicky E. Jones
The US Oncology Network
James Hathorn, MD
The US Oncology Network
Rama Balaraman, MD
The US Oncology Network
Philip Dien, MD
The US Oncology Network
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”